The Flexible, Versatile and Fast GreGT Platform of Fully Deleted Helper-Virus Independent Adenoviral Vectors
Yan Qi, Xianghua Zhang, Janae Wheeler Cull, Charles Wall, William Maslanik, Uwe D. Staerz
Abstract
Gene transfer (GT) vectors have diverse applications. They have been used to restore cellular activities by reconstituting normal cellular functions, by delivering therapeutic compounds, and by priming immune responses as genetic vaccines. Viruses, natures gene delivery vehicles, have formed the basis of most GT vectors. The biology of the underlying virus may, however, hamper their use. For instance, retroviral vectors with their ability to integrate into the genome, may cause malignant transformations. Vectors designed as minor variants of the relatively benign, yet complex adenovirus (Ad) excite vigorous immune responses, thus limiting their therapeutic effects. Deleting Ad vectors of all endogenous Ad genes brought their beneficial features to the front, such as their ability to transduce cells of many types with high efficiency and to deliver large genetic payloads. Earlier production schemes of fully deleted Ad (fdAd) vectors depended on helper virus constructs to deliver the vector production information in trans. They suffered from contaminations with the helper virus or the recombination of replication competent adenoviruses (RCA). We previously developed a novel transfection-based helper virus-independent Ad vector encapsidation technology that avoided these pitfalls. It was built on a vector genome and a vector packaging module. We have now optimized our approach into the GreGT plug-and-play platform so that a new vector can be delivered in about four weeks. The GreGT system is built upon a set of base vector genome modules that can be quickly loaded with a new application, and a set of packaging modules that allow their encapsidation into capsids of different Ad serotypes. As both components can be freely combined, the GreGT platform is endowed with high degrees of flexibility and versatility. Finally, the deletion of all endogenous Ad genes from the vector genome limits the interference by anti-Ad immune responses. It also increases the genetic payload capacity to levels unique to this system.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 2
- FWCI
- 0.53
- Field percentile
- top 35%
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- A Potent Pandemic Avian Influenza Virus Vaccine Based on a 4th Generation Fully Deleted Adenoviral Vector
Yan Qi, E. Bart Tarbet, … Uwe D. Staerz·bioRxiv·Dec 30, 2024
- A Highly Protective Clade 1 and 2 Cross-Reactive Pandemic Influenza Virus Vaccine Based on a 4th Generation Fully Deleted Adenoviral Vector of a Rare Serotype
Yan Qi, Richard Bowen, … Uwe D. Staerz·bioRxiv·Apr 30, 2025
- Human AdV-20-42-42, a promising novel adenoviral vector for gene therapy and vaccine product development
M. Z. Ballmann, S. Raus, … A. H. Baker·bioRxiv·Mar 11, 2021
- Genome-replicating HC-AdV, a novel high-capacity adenoviral vector class featuring enhanced in situ payload expression
Jonas Kolibius, Fabian Weiss, … Andreas Plückthun·Molecular Therapy — Methods & Clinical DevelopmentPeer-reviewed·Sep 1, 2025
- Seroprevalence and cross-reactivity of neutralizing antibodies to six types of adenoviruses
Olga V. Zubkova, Tatiana A. Ozharovskaia, … Gintsburg Al·bioRxiv·Dec 26, 2024
- Non-clinical safety of GRAd vector-based COVID-19 and HIV vaccines supports a platform regulatory approach
Reji Paalangara, Stéphanie Gohin, … Stefania Capone·VaccinesPeer-reviewed·Feb 6, 2026